TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02123615
Drug: Adverse Reactions of Gammagard subdermally at Week 24
Normalized name: Gammagard
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adverse Reactions of Gammagard subdermally at Week 24, in number of Local Reactions, Headache, Fever, Nausea, Vomiting, Fatigue, Diarrhea, Asthma, Oropharyngeal, and Abdominal Pain.
Study: NCT02123615
Drug: Adverse Reactions of Gammagard subdermally at Week 36
Normalized name: Gammagard
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adverse Reactions of Gammagard subdermally at Week 36, in number of Local Reactions, Headache, Fever, Nausea, Vomiting, Fatigue, Diarrhea, Asthma, Oropharyngeal, and Abdominal Pain.
Study: NCT01846221
Drug: Fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Subjects randomized to fentanyl will receive 100 mcg fentanyl and 12.5 mg bupivacaine in 10 ml of volume.
Study: NCT02920541
Drug: S 055746
Approvals — FDA: no, EMA: no, PMDA: no
Description: S 055746, per os administration, from 50 to 2000 mg once a day during a 21-day cycle. Participants will receive 21-day cycles of treatment until a discontinuation criterion is met.
Study: NCT01609166
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo cream application in the other side of the body, twice a day for 6 months
Study: NCT01947491
Drug: Comp01 Lotion
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02128425
Drug: FOLFOXIRI
Approvals — FDA: no, EMA: no, PMDA: no
Description: irinotecan\* 165 mg/m² + oxaliplatin 85 mg/m² + leucovorin 200 mg/m² + 5-FU 3200 mg/m² cont. inf. 46h all on day 1 of each 2 weeks cycle~\*reduced in UGT1A1 7/7 patients
Study: NCT02128425
Drug: FOLFOX
Approvals — FDA: no, EMA: no, PMDA: no
Description: oxaliplatin 85 mg/m² + leucovorin 400 mg/m² +5-FU 400mg/m² bolus iv.+ 5-FU 2400 mg/m² cont. inf. 46h all on day 1 of each 2 weeks cycle
Study: NCT03320850
Drug: Placebo and Hydrogel admixture
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo and Hydrogel admixture administered as a single intravesical instillation
Study: NCT00327743
Drug: capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: oral, twice daily, Day 1-Day 14 of a 21-day cycle
Study: NCT03091881
Drug: Placebos
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebos will be given 10 min before spinal block
Study: NCT02031640
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02091375
Drug: GWP42003-P 20 mg/kg/day Dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: GWP42003-P was an oral solution containing 100 mg/milliliter (mL) cannabidiol (CBD) dissolved in the excipients, sesame oil and anhydrous ethanol (79 mg/mL), with added sweetener (0.5 mg/mL sucralose) and strawberry flavoring (0.2 mg/mL).
Study: NCT02205008
Drug: adjuvant systemic chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: adjuvant systemic chemotherapy with S-1 (\<1.25m2:40mg, 1.25-1.5m2:50mg, \>1.5m2:60mg, bid)
Study: NCT01755702
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT01755702
Drug: Experimental paracetamol + caffeine formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: experimental paracetamol + caffeine formulation
Study: NCT01755702
Drug: ibuprofen marketed formulation
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: ibuprofen marketed formulation
Study: NCT01755702
Drug: Paracetamol marketed formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paracetamol marketed formulation
Study: NCT00448890
Drug: GSK729327
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablets
Study: NCT00448890
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK729327 Matching placebo - Tablets
Study: NCT01747538
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solution for subcutaneous injection
Study: NCT00571701
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: similar appearing capsules containing inert ingredients
Study: NCT03540875
Drug: Remifentanil
Normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The dosage is modified automatically by the device or according to the new medical prescription.
Study: NCT03228524
Drug: D-Aspartate
Normalized name: D-Aspartate oxidase
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will be randomized to receive oral D-aspartatoe (2660 mg, once daily) or placebo,as an addition to conventional therapy as indicated by physicians, for a 6 weeks period.
Study: NCT03228524
Drug: Placebo Oral Tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT03676296
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo in granules (with the same excipients as the puerarin supplement but without puerarin) taken orally for 12 weeks
Study: NCT04033341
Drug: LY3214996
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally
Study: NCT04033341
Drug: [14C]-LY3214996
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally
Study: NCT02184585
Drug: Treatment sequence A
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: FDC 1 - Fixed dose combination capsule of dutasteride and tamsulosin hydrochloride (0.5 mg/0.2 mg). Each capsule will contain dutasteride (0.5 mg) (CJ) and tamsulosin pellets (0.2 mg) version 1.
Study: NCT02184585
Drug: Treatment sequence B
Approvals — FDA: no, EMA: no, PMDA: no
Description: FDC 2 - Fixed dose combination capsule of dutasteride and tamsulosin hydrochloride (0.5 mg/0.2 mg). Each capsule will contain dutasteride (0.5 mg) (CL) and tamsulosin pellets (0.2 mg) version 2.
Study: NCT02184585
Drug: Treatment sequence C
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Co-administration of dutasteride 0.5 mg capsule (Oblong, size 6, dull yellow capsules: Commercially available) and tamsulosin hydrochloride 0.2 mg tablet (White, round standard convex tablet: Commercially available).
Study: NCT01329809
Drug: Recombinant Vaccinia GM-CSF; RAC VAC GM-CSF (JX-594)
Approvals — FDA: no, EMA: no, PMDA: no
Description: intratumoral or intravenous dosage: 10e9 pfu Intravenous: administered over 60 minutes Intratumoral: direct injection into a single liver lesion
Study: NCT01128101
Drug: Spironolactone
Normalized name: Spironolactone
DrugBank: Spironolactone (DB00421)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The group who receive spironolactone, the dose employed will be 25 mg each other day and titrated to 25 mg daily according to potassium.
Study: NCT01238640
Drug: Code STD
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg Single-dose of experimental nicotine product coded STD
Study: NCT01238640
Drug: Code STE
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 2 mg Single-dose of experimental nicotine product coded STE
Study: NCT01238640
Drug: Nicorette Microtab
Approvals — FDA: no, EMA: no, PMDA: no
Description: A comparative 2 mg Single-dose of marketed tablet
Study: NCT03596281
Drug: pegylated liposomal doxorubicin (PLD)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 or 20 or 30 mg/m² Q3W IV
Study: NCT01205126
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be administered to the participants receiving hydromorphone HCl or oxycodone HCl CR along with the study treatment to maintain necessary blinding.
Study: NCT00768755
Drug: chemotherapy
Normalized name: Chemotherapy Glove SML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pemetrexed(500mg/m2)/Cisplatin(75mg/m2) x max 6 cycles
Study: NCT02662764
Drug: Zalviso™ 15 mcg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zalviso™ (sufentanil sublingual tablet system) 15 mcg. Tablets to be self-administered by the patient as needed for pain, no more than every 20 minutes, for 24 hours and up to 72 hours
Study: NCT03700333
Drug: S-1 therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: accept S-1(50mg, twice a day, morning and night, if\<1.5m2; 75mg, twice a day, morning and night,if \>1.5m2 )chemotherapy after finishing first-line therapy(\>21 days).
Study: NCT01250535
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: po, once a day, days 1 through 14
Study: NCT01250535
Drug: Lovastatin
Normalized name: Lovastatin
DrugBank: Lovastatin (DB00227)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 40 mg, po, once a day, days 1 through 14
Study: NCT02565719
Drug: REP 2139-Mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: REP 2139-Mg = magnesium chelate complex of REP 2139
Study: NCT02565719
Drug: REP 2165-Mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: REP 2165-Mg = magnesium chelate complex of REP 2165
Study: NCT02445404
Drug: fractionated ICED
Approvals — FDA: no, EMA: no, PMDA: no
Description: ifosfamide, 1.67 g/m² IV day1\~3 carboplatin, AUC =5 IV day1 etoposide, 100mg/m² IV day1\~3 dexamethasone 40 mg PO or IV day1\~4 every 3 weeks
Study: NCT04323306
Drug: MMV688533
Approvals — FDA: no, EMA: no, PMDA: no
Description: Investigational medicinal product
Study: NCT00855595
Drug: Doxycycline (Oracea)
Normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants received systemic doxycycline 40 mg once daily for 12 week
Study: NCT00089778
Drug: Fibroblast growth factor 5 (FGF-5):172-176/217-220
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two 1 ml injection in the anterior thigh deep subcutaneous tissue within 2c of each other.
Study: NCT00372710
Drug: Zoledronic acid
Normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT02149823
Drug: Syntocinon 24 Intranasal Units (IU)
Normalized name: influenza A virus (H1N1) antigen
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02149823
Drug: Syntocinon 40 Intranasal Units (IU)
Normalized name: influenza A virus (H1N1) antigen
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02149823
Drug: Intranasal Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01380717
Drug: Beta-blocker, ACE-inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta-blocker: 50- 100 mg 1-2 times a day. ACEi: 5-10 mg once a day
Study: NCT04525079
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo-matching CT-P59
Study: NCT04555096
Drug: GC4419
Approvals — FDA: no, EMA: no, PMDA: no
Description: 180 Minute IV Infusion
Study: NCT04555096
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 180 Minute IV Infusion
Study: NCT02050815
Drug: MEK162
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02815865
Drug: Dinoprostone
Normalized name: Dinoprostone
DrugBank: Dinoprostone (DB00917)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dinoprostone 3 mg will be inserted to the posterior fornix
Study: NCT00851513
Drug: Depmedrol
Approvals — FDA: no, EMA: no, PMDA: no
Description: local steroids
Study: NCT01772199
Drug: GSK239512
Approvals — FDA: no, EMA: no, PMDA: no
Description: White to almost white, round tablets. Once daily orally, started at 10 mcg and titrated to the maximum tolerated dose, Up to the highest dose of 80 mcg (10 mcg first week, 20 mcg second week, 40 mcg third week, 80 mcg fourth week) followed by 44 week maintenance treatment period
Study: NCT00723099
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT01772199
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: White to almost white, round tablets. Once daily orally.
Study: NCT02100670
Drug: 1% diclofenac sodium plus 3% menthol
Approvals — FDA: no, EMA: no, PMDA: no
Description: To be applied four times daily for 10 days.
Study: NCT02100670
Drug: 1% diclofenac sodium plus 0.09% menthol
Approvals — FDA: no, EMA: no, PMDA: no
Description: To be applied four times daily for 10 days.
Study: NCT04322006
Drug: TJ004309
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibody to CD73
Study: NCT01121302
Drug: AZD5213
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1 mg, 0.3 mg, 1 mg, 2 mg, 4 mg, 8 mg, 16 mg, 32 mg oral solution, single ascending doses
Study: NCT01121302
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00571766
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo 2 g twice a day for 14 weeks
Study: NCT03224221
Drug: fluorouracil and platinum
Normalized name: platinum
DrugBank: Platinum (DB12257)
Approvals — FDA: no, EMA: no, PMDA: no
Description: the dosage of the fluorouracil and platinum need to be determined by the doctors according to the actual condition of the patients
Study: NCT01040390
Drug: Lappa Arctium
Approvals — FDA: no, EMA: no, PMDA: no
Description: To start with subjects will be prescribed Lappa Arctium in 6 potency to be taken in form of pills 4 times a day for seven days. Dosage and frequency will be changed, if required, based on the condition of subject and their response according to homoeopathic principles.
Study: NCT00405457
Drug: Restasis, Optive Tears
Approvals — FDA: no, EMA: no, PMDA: no
Description: Restasis and Optive Tears use twice daily more frequently if needed
Study: NCT02131818
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The patient will be received placebo 2 capsules orally bid pc for 5 days
Study: NCT01144676
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The first vaginal ring will be removed on Day 28, and a new vaginal ring will be reinserted after 3 days, on day 31, for another 28 days.
Study: NCT01144676
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The first vaginal ring will be removed on day 35 and the new vaginal ring will be reinserted after 3 days, on day 38, for another 21 days. A third vaginal ring will be inserted immediately following removal of second ring on Day 59 and will be worn for 24 hours.
Study: NCT00355576
Drug: Celecoxib
Normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Celecoxib 400 mg BID with creatine 10 g BID if randomized to the Celecoxib + Creatine study arm.
Study: NCT00355576
Drug: Creatine
Normalized name: Creatine
DrugBank: Creatine (DB00148)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 10 g BID for either study arm
Study: NCT00355576
Drug: Minocycline
Normalized name: Minocycline
DrugBank: Minocycline (DB01017)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Minocycline 100 mg BID with creatine 10 g BID if randomized to the Minocycline + Creatine study arm
Study: NCT01760005
Drug: Matching Placebo (Gantenerumab)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous injection of placebo every 4 weeks
Study: NCT01760005
Drug: Matching Placebo (Solanezumab)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion of placebo every 4 weeks
Study: NCT01760005
Drug: E2814
Normalized name: Estradiol
DrugBank: Estradiol acetate (DB13952)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administered intravenously in a blinded fashion
Study: NCT03147586
Drug: Bio-tech and omega-3 plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: immune nutrition : Bio-tech ( multivitamins and essential amino acids), and omega-3 plus (omega-3 fatty acids)
Study: NCT03147586
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo
Study: NCT00824382
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 puffs delivered by the RespimatÂ® inhaler
Study: NCT01124552
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo Comparator
Study: NCT03977753
Drug: 2LVERU® or 2LVERU® JUNIOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: The treatment schema consists in taking the content of one capsule a day, 15-30 minutes before breakfast, on an empty stomach, sequentially, according to capsules' numerical order: 1 through 10. When capsule number 10 is taken, capsule 1 of the next blister should be taken on the next day to continue the treatment.~The duration of treatment will be 6 months of continuous intake of the content of 1 capsule/day.
Study: NCT03977753
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The treatment schema consists in taking the content of one capsule a day, 15-30 minutes before breakfast, on an empty stomach, sequentially, according to capsules' numerical order: 1 through 10. When capsule number 10 is taken, capsule 1 of the next blister should be taken on the next day to continue the treatment.~The duration of treatment will be 6 months of continuous intake of the content of 1 capsule/day.
Study: NCT01852331
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The placebo granules are prepared to be identical to PGD granules in smell, taste and color.
Study: NCT00749944
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg tablets twice daily by mouth (after one week of uptitration: 0.5mg once daily for three days, 0.5mg twice daily for four days)
Study: NCT00000617
Drug: azithromycin
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01721694
Drug: azithromycin 1.5%/Loteprednol 0,5% + placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 drop, AO, QID
Study: NCT01721694
Drug: azithromycin 1.5% + Loteprednol 0,5% (separately)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 drop, QID, AO
Study: NCT00000250
Drug: 40% N2O
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will inhale 40% N2O then immerse forearm in warm water and cold water
Study: NCT00342563
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT01544959
Drug: fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Use of esmolol and metoprolol compared to use of fentanyl for hemodynamic control during general anesthesia. At induction, fentanyl (2 mcg/kg) is replaced by esmolol (1 mg/kg). During the case, with a standardised anesthesia, response to surgical stimulation will be medicated either by fentanyl (50 mcg aliquot) or metropolol (2.5 mg), for a maximum of 6 doses. After this, fentanyl will be given unblindly.
Study: NCT00697541
Drug: Advanced Eye Relief
Normalized name: Advanced Eye Relief Dry Eye
Approvals — FDA: no, EMA: no, PMDA: no
Description: One 1-g application of 0.18% COL-118 facial gel (1.8 mg brimonidine) administered topically plus one drop of Advanced Eye Relief™ in each eye, once in the morning. 1 g of 0.18% COL-118 facial gel is reapplied once after 4 hours
Study: NCT01859793
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo in appearance given once/day orally
Study: NCT02013336
Drug: MM-398 (Irinotecan Sucrosofate Liposome Injection) plus cyclophosphamide
Normalized name: Irinotecan liposome injection
DrugBank: Irinotecan (DB00762)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: chemotherapy
Study: NCT00058968
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03966456
Drug: Chemotherapy
Normalized name: Chemotherapy Glove SML
Approvals — FDA: no, EMA: no, PMDA: no
Description: compare the effecy and safety of 4 PD-1 agents single and combined with chemotherapy in chinese people.
Study: NCT00326781
Drug: Nicoderm Transdermal Patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: The dosing schedule is as follows: 4 weeks of 21mg per 24 hours, 2 weeks of 14mg per 24 hours, and 2 weeks of 7mg per 24 hours. Treatment lasted 8 weeks.
Study: NCT03192995
Drug: Placebo Oral Tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo 20 mg. tablet
Study: NCT03361865
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo administered orally twice daily.
Study: NCT00079586
Drug: Heparin
Normalized name: Heparin
DrugBank: Heparin (DB01109)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Unfractionated Heparin per institutional practice
Study: NCT01513902
Drug: CP-690,550
Approvals — FDA: no, EMA: no, PMDA: no
Description: CP-690,550 will be administered orally twice daily according to the dosing regimen provided below. Oral solution will be used for children weighing \<40 kg. Oral tablets will be used for children weighing ≥40 kg. Children aged 12 to less than 18 years who are unable to swallow tablets will have the option of taking oral solution. Body Weight (kg) Dose (mg) Volume (mL) 5-11 1 1; 12-18 1.5 1.5; 19-24 2 2; 25-31 2.5 2.5; 32-39 3 3; ≥40 5 5
Study: NCT01513902
Drug: CP-690,550
Approvals — FDA: no, EMA: no, PMDA: no
Description: CP-690,550 will be administered orally twice daily according to the dosing regimen provided below. Oral solution will be used for children weighing \<40 kg. Oral tablets will be used for children weighing ≥40 kg. Children less than 12 years of age with a body weight of ≥40 kg will have the option of taking oral solution or tablets. Body Weight (kg) Dose (mg) Volume (mL) 5-11 1 1; 12-18 1.5 1.5; 19-24 2 2; 25-31 2.5 2.5; 32-39 3 3; ≥40 5 5
Study: NCT01513902
Drug: CP-690,550
Approvals — FDA: no, EMA: no, PMDA: no
Description: CP-690,550 will be administered orally twice daily according to the dosing regimen provided below. Children with a body weight ≥30 kg will have the option of taking oral solution or tablets, and children weighing \<30 kg will be dosed with the oral solution. Body Weight (kg) Dose (mg) Volume (mL) 5-6 1 1; 7-9 1.5 1.5; 10-12 2 2; 21-15 2.5 2.5; 16-19 3 3; 20-22 3.5 3.5; 23-26 4 4; 27-29 4.5 4.5; ≥30 5 5
Study: NCT01424514
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo intra nasal
Study: NCT00546117
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo Solutab in 15 and 30 mg dosages.
Study: NCT03048123
Drug: Folfox Protocol
Normalized name: Olay Professional Acne Protocol
Approvals — FDA: no, EMA: no, PMDA: no
Description: oxaliplatin,leucovorin and 5-FU
Study: NCT03048123
Drug: TACE Drug Protocol
Approvals — FDA: no, EMA: no, PMDA: no
Description: lipiodol mixed with chemotherapy drugs(EADM , lobaplatin, and MMC) followed by polyvinyl alcohol particles (PVA)
Study: NCT01768975
Drug: OLT1177 Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mL per dose, applied 3 times per day on Days 1 - 13 with only one dose administered on Day 14, assuming TID on Day 1
Study: NCT00088959
Drug: celecoxib
Normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given orally
Study: NCT02227316
Drug: IV Ibuprofen
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Uterine fibroid embolization
Study: NCT02227316
Drug: IV Acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Uterine fibroid embolization
Study: NCT02227316
Drug: Intravenous placebo/Intravenous placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Uterine fibroid embolization
Study: NCT01323153
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral doses of matching placebo to dalcetrapib once daily for 20 weeks